ES2805037T3 - Compuestos y métodos para tratar la inflamación - Google Patents

Compuestos y métodos para tratar la inflamación Download PDF

Info

Publication number
ES2805037T3
ES2805037T3 ES17703290T ES17703290T ES2805037T3 ES 2805037 T3 ES2805037 T3 ES 2805037T3 ES 17703290 T ES17703290 T ES 17703290T ES 17703290 T ES17703290 T ES 17703290T ES 2805037 T3 ES2805037 T3 ES 2805037T3
Authority
ES
Spain
Prior art keywords
acid
composition
kemerin
fragment
analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17703290T
Other languages
English (en)
Spanish (es)
Inventor
Charles Cohen
Krishna Kumar
Alan S Kopin
Benjamin N Harwood
Venkata S Raman
Pedram Hamrah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tufts Medical Center Inc
Tufts University
On Target Therapeutics LLC
Original Assignee
Tufts Medical Center Inc
Tufts University
On Target Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts Medical Center Inc, Tufts University, On Target Therapeutics LLC filed Critical Tufts Medical Center Inc
Application granted granted Critical
Publication of ES2805037T3 publication Critical patent/ES2805037T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
ES17703290T 2016-01-22 2017-01-23 Compuestos y métodos para tratar la inflamación Active ES2805037T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662286070P 2016-01-22 2016-01-22
PCT/US2017/014605 WO2017127827A1 (en) 2016-01-22 2017-01-23 Compounds and methods for treating inflammation

Publications (1)

Publication Number Publication Date
ES2805037T3 true ES2805037T3 (es) 2021-02-10

Family

ID=57963487

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17703290T Active ES2805037T3 (es) 2016-01-22 2017-01-23 Compuestos y métodos para tratar la inflamación

Country Status (7)

Country Link
US (3) US11197906B2 (enExample)
EP (1) EP3405208B1 (enExample)
JP (3) JP6924211B2 (enExample)
AU (1) AU2017210118B2 (enExample)
CA (1) CA3012190A1 (enExample)
ES (1) ES2805037T3 (enExample)
WO (1) WO2017127827A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10233219B2 (en) 2013-04-12 2019-03-19 Tufts Medical Center Methods and systems for designing and/or characterizing soluble lipidated ligand agents
WO2017127827A1 (en) 2016-01-22 2017-07-27 Tufts Medical Center Compounds and methods for treating inflammation
JP7251036B2 (ja) * 2018-06-28 2023-04-04 ポーラ化成工業株式会社 皮膚老化改善剤のスクリーニング方法
WO2021021915A1 (en) * 2019-08-01 2021-02-04 Okyo Pharma Limited Compositions comprising chemerin analogs and methods of use
WO2023220676A2 (en) * 2022-05-12 2023-11-16 Okyo Pharma Limited Formulation for treating dry eye disease

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6416738B1 (en) 1973-12-07 2002-07-09 Neorx Corporation Pretargeting methods and compounds
US5200473A (en) 1988-03-25 1993-04-06 Jeanneret Gris Gilbert Chelating resins and method for their use in the extraction of metal ions
JP3507486B2 (ja) 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US6365156B1 (en) 1999-04-16 2002-04-02 Osel, Inc. Method for improving the half-life of soluble viral-specific ligands on mucosal membranes
IL160142A0 (en) 2001-08-17 2004-06-20 Anosys Inc Methods and compounds for the targeting of protein to exosomes
US7169892B2 (en) 2003-01-10 2007-01-30 Astellas Pharma Inc. Lipid-peptide-polymer conjugates for long blood circulation and tumor specific drug delivery systems
US20060263336A1 (en) 2003-03-24 2006-11-23 Caplan Arnold I Cell targeting methods and compositions
WO2005121755A1 (en) 2004-06-14 2005-12-22 Commonwealth Scientific And Industrial Research Organisation Cell free g-protein coupled receptor and ligand assay
CN101947310A (zh) 2004-10-27 2011-01-19 丹佛大学 促肾上腺皮质激素类似物以及相关方法
CA2611365C (en) 2005-06-14 2014-02-11 Cellzome Ag Process for the identification of novel enzyme interacting compounds
US8242058B2 (en) 2006-07-21 2012-08-14 Wisconsin Alumni Research Foundation Reagents and methods for appending functional groups to proteins
JP2010229093A (ja) 2009-03-27 2010-10-14 Banyu Pharmaceut Co Ltd 新規ＣｈｅｍｅｒｉｎＲアゴニスト
GB0914110D0 (en) 2009-08-12 2009-09-16 Medical Res Council Peptide libraries
US20120245229A1 (en) 2009-09-15 2012-09-27 Ru-Rong Ji Method for treating neuropathic pain
EP2533764A4 (en) 2010-02-08 2016-08-31 Univ Nebraska BIOMINERAL AND METAL BINDING LIPOSOME, THEIR SYNTHESIS AND METHOD FOR THE PRODUCTION THEREOF
US8883177B2 (en) 2011-06-28 2014-11-11 Nian Wu Pharmaceutical compositions for parenteral administration
EP2766032A4 (en) * 2011-10-13 2015-04-29 Thomas Gadek TOPICAL FORMULATIONS OF PEPTIDES CHÉMÉRINE C15 FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS
US10233219B2 (en) 2013-04-12 2019-03-19 Tufts Medical Center Methods and systems for designing and/or characterizing soluble lipidated ligand agents
WO2017127827A1 (en) 2016-01-22 2017-07-27 Tufts Medical Center Compounds and methods for treating inflammation

Also Published As

Publication number Publication date
US12053501B2 (en) 2024-08-06
JP2019507182A (ja) 2019-03-14
US11197906B2 (en) 2021-12-14
AU2017210118B2 (en) 2023-05-04
JP2023059999A (ja) 2023-04-27
EP3405208A1 (en) 2018-11-28
AU2017210118A1 (en) 2018-08-09
JP2021169531A (ja) 2021-10-28
CA3012190A1 (en) 2017-07-27
WO2017127827A1 (en) 2017-07-27
US20240325486A1 (en) 2024-10-03
EP3405208B1 (en) 2020-04-29
JP6924211B2 (ja) 2021-08-25
US20220054581A1 (en) 2022-02-24
JP7432028B2 (ja) 2024-02-15
US20190022168A1 (en) 2019-01-24

Similar Documents

Publication Publication Date Title
US12053501B2 (en) Methods for treating symptoms of dry eye disease
US20220313770A1 (en) Immunotherapy for angiogenic disease
ES2903448T3 (es) Peptidomiméticos de adiponectina para el tratamiento de trastornos oculares
TWI635868B (zh) 長效胜肽類似物
CN111032069B (zh) Piezo调节剂在制备药物中的用途
ES2393462T3 (es) Péptido útil para inhibir la actividad del receptor de prosta-glandina F2X
ES2863701T3 (es) Inhibidores de la dipeptidil peptidasa-4 para el tratamiento tópico ocular de enfermedades neurodegenerativas de la retina
JP7651553B2 (ja) ケメリン類似体を含む組成物とその使用方法
HK40000831A (en) Compounds and methods for treating inflammation
HK40000831B (en) Compounds and methods for treating inflammation
EP4007636B1 (en) Compositions comprising bovine adrenal medulla 8-22 (bam8-22) peptide analogs and methods of use
WO2023220676A9 (en) Chemerin-containing formulation for treating dry eye disease
HK40075089B (en) Compositions comprising chemerin analogs and methods of use
HK40075089A (en) Compositions comprising chemerin analogs and methods of use
KR20210062650A (ko) 펩티드 및 이의 의학적 용도